Zhao Bingbing, Sun Zhenzhao, Wang Shida, Shi Zhibin, Jiang Yongping, Wang Xiurong, Deng Guohua, Jiao Peirong, Chen Hualan, Wang Jingfei
State Key Laboratory for Animal Disease Control and Prevention & National Data Center for Animal Infectious Diseases, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin, People's Republic of China.
College of Veterinary Medicine, South China Agricultural University, Guangzhou, People's Republic of China.
J Virol. 2025 Jan 31;99(1):e0140024. doi: 10.1128/jvi.01400-24. Epub 2024 Dec 20.
Neutralizing antibodies (nAbs) are important for the treatment of emerging viral diseases and for effective vaccine development. In this study, we generated and evaluated three nAbs (1H9, 2D7, and C4H4) against H7N9 influenza viruses and found that they differ in their ability to inhibit viral attachment, membrane fusion, and egress. We resolved the cryo-electron microscopy (cryo-EM) structures of H7N9 hemagglutinin (HA) alone and in complex with the nAb antigen-binding fragments (Fabs) and identified the HA head-located epitope for each nAb, thereby revealing the molecular basis and key residues that determine the differences in these nAbs in neutralizing H7N9 viruses. Moreover, we found that the humanized nAb CC4H4 provided complete protection in mice against death caused by a lethal H7N9 virus infection, even when nAb was given 3 days after the mice were infected. These findings provide new insights into the neutralizing mechanism and structural basis for the rational design of H7N9 virus vaccines and therapeutics.IMPORTANCEH7N9 viruses have caused severe infections in both birds and humans since their emergence in early 2013 in China. Their persistent presence and variation in avian populations pose a significant threat to both poultry and humans. There are no treatments for human infections. In this study, we thoroughly investigated the neutralization mechanisms, structural basis, and therapeutic effects of three nAbs (1H9, 2D7, and C4H4) against H7N9 viruses. We revealed the molecular determinants underlying the varied performances of the three nAbs in neutralizing H7N9 viruses and protecting H7N9-infected mice. These insights provide a solid foundation for the rational design of vaccines and therapeutics against H7N9 viruses.
中和抗体(nAbs)对于新兴病毒性疾病的治疗以及有效的疫苗开发至关重要。在本研究中,我们制备并评估了三种针对H7N9流感病毒的中和抗体(1H9、2D7和C4H4),发现它们在抑制病毒附着、膜融合和释放的能力上存在差异。我们解析了单独的H7N9血凝素(HA)以及与中和抗体抗原结合片段(Fabs)形成复合物的低温电子显微镜(cryo-EM)结构,并确定了每种中和抗体在HA头部的表位,从而揭示了决定这些中和抗体在中和H7N9病毒时存在差异的分子基础和关键残基。此外,我们发现人源化中和抗体CC4H4能在小鼠中提供完全保护,使其免受致死性H7N9病毒感染导致的死亡,即便在小鼠感染后3天给予该中和抗体。这些发现为H7N9病毒疫苗和治疗药物的合理设计提供了关于中和机制和结构基础的新见解。
重要性
自2013年初在中国出现以来,H7N9病毒已在禽类和人类中引发严重感染。它们在禽类群体中的持续存在和变异对家禽和人类都构成了重大威胁。目前尚无针对人类感染的治疗方法。在本研究中,我们全面研究了三种针对H7N9病毒的中和抗体(1H9、2D7和C4H4)的中和机制、结构基础和治疗效果。我们揭示了这三种中和抗体在中和H7N9病毒以及保护感染H7N9的小鼠方面表现各异的分子决定因素。这些见解为针对H7N9病毒的疫苗和治疗药物的合理设计奠定了坚实基础。